<p>OmniAb, Inc.（NASDAQ:OABI - 获取免费报告）的股票在周三的午盘交易中上涨了 3.3%。该公司的股票最高交易价格为 1.9250 美元，最后交易价格为 1.90 美元。在午盘交易中，共成交 264,447 股，较平均交易量 547,383 股下降了 52%。该股票此前收盘价为 1.84 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 12 月 22 日的研究报告中重申了对 OmniAb 股票的 “卖出（e+）” 评级。三位研究分析师给予该股票买入评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，OmniAb 目前的共识评级为 “适度买入”，共识目标价为 6.67 美元。</p>
<p><strong>阅读我们对 OmniAb 的最新股票分析</strong></p>
<h2>OmniAb 股票表现</h2>
<p>该公司的 50 日简单移动平均线为 1.80 美元，200 日简单移动平均线为 1.78 美元。该股票的市值为 2.7352 亿美元，市盈率为-3.28，贝塔值为 0.13。</p>
<p>OmniAb（NASDAQ:OABI - 获取免费报告）最近于 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.14 美元，超出市场共识预期的-0.15 美元，超出幅度为 0.01 美元。OmniAb 的股本回报率为-23.14%，净利润率为-301.83%。该公司在本季度的收入为 224 万美元，而分析师预期为 564 万美元。整体来看，股票研究分析师预测 OmniAb, Inc.在本年度将发布-0.61 美元的每股收益。</p>
<h2>OmniAb 内部买卖情况</h2>
<p>在其他 OmniAb 新闻中，首席财务官 Kurt A. Gustafson 于 12 月 8 日星期一出售了 23,922 股该公司的股票。股票以平均价格 1.96 美元出售，总交易额为 46,887.12 美元。交易后，首席财务官持有该公司 252,688 股股票，价值约 495,268.48 美元。此交易代表其持股比例下降了 8.65%。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接获取。此外，首席执行官 Matthew W. Foehr 于 12 月 8 日星期一出售了 13,666 股该公司的股票。股票以平均价格 1.96 美元出售，总交易额为 26,785.36 美元。出售后，首席执行官持有该公司 4,360,083 股股票，价值 8,545,762.68 美元。此交易代表其持股比例下降了 0.31%。有关此销售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售公司股票 45,632 股，价值 89,439 美元。公司内部人士持有公司股票的 8.60%。</p>
<h2>机构投资者对 OmniAb 的看法</h2>
<p>一些机构投资者最近增加或减少了对该公司的持股。俄亥俄州公共雇员退休系统在第二季度购买了 OmniAb 的新头寸，价值约 168,000 美元。Connors Investor Services Inc.在第二季度将其在 OmniAb 的持股增加了 25.0%。Connors Investor Services Inc.目前持有 62,000 股该公司的股票，价值 108,000 美元，此前在上个季度又购买了 12,389 股。Towerview LLC 在第二季度将其在 OmniAb 的持股增加了 43.3%。Towerview LLC 目前持有 831,100 股该公司的股票，价值 1,446,000 美元，此前在上个季度又购买了 251,100 股。Private Management Group Inc.在第二季度将其在 OmniAb 的持股增加了 1.1%。Private Management Group Inc.目前持有 2,558,045 股该公司的股票，价值 4,451,000 美元，此前在上个季度又购买了 28,286 股。最后，Isthmus Partners LLC 在第二季度将其在 OmniAb 的持股增加了 21.2%。Isthmus Partners LLC 目前持有 568,043 股该公司的股票，价值 988,000 美元，此前在上个季度又购买了 99,336 股。目前 72.08% 的股票由机构投资者和对冲基金持有。</p>
<h2>OmniAb 公司简介</h2>
<p>（获取免费报告）</p>
<p>OmniAb, Inc. NASDAQ: OABI 是一家生物技术公司，专注于治疗性抗体的发现和开发。该公司的综合抗体发现平台结合了专有的转基因动物模型、体外筛选和计算机工程，以加速候选药物的识别和优化。OmniAb 提供按服务收费的合作和许可协议，使生物制药合作伙伴能够利用其技术组合，涵盖肿瘤学、免疫学和其他治疗领域。</p>
<p>OmniAb 成立于 2016 年，总部位于华盛顿州西雅图，于 2021 年 5 月上市。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 OmniAb 更好</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 OmniAb 吗？</h2>
<p>在你考虑 OmniAb 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 OmniAb 并不在名单上。</p>
<p>虽然 OmniAb 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OABI

<p>OmniAb (NASDAQ:OABI) 的股价上涨了 3.3%，达到 1.90 美元，交易量较平均水平下降了 52%。分析师维持 “适度买入” 的共识评级，目标价为 6.67 美元。公司报告的季度每股收益为（0.14 美元），超出预期，但收入为 224 万美元，未达到预期。公司高管进行了减持，首席财务官和首席执行官都减少了持股。机构投资者持有 72.08% 的股份。OmniAb 专注于治疗性抗体的开发，并于 2021 年 5 月上市</p>

<p>Shares of OmniAb, Inc. (NASDAQ:OABI - Get Free Report) traded up 3.3% during mid-day trading on Wednesday . The company traded as high as $1.9250 and last traded at $1.90. 264,447 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 547,383 shares. The stock had previously closed at $1.84.</p>
<div class="lb-trans"><p>OmniAb, Inc.（NASDAQ:OABI - 获取免费报告）的股票在周三的午盘交易中上涨了 3.3%。该公司的股票最高交易价格为 1.9250 美元，最后交易价格为 1.90 美元。在午盘交易中，共成交 264,447 股，较平均交易量 547,383 股下降了 52%。该股票此前收盘价为 1.84 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of OmniAb in a research report on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, OmniAb presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $6.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 22 日的研究报告中重申了对 OmniAb 股票的 “卖出（e+）” 评级。三位研究分析师给予该股票买入评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，OmniAb 目前的共识评级为 “适度买入”，共识目标价为 6.67 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on OmniAb</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 OmniAb 的最新股票分析</strong></p>
</div><h2>OmniAb Stock Performance</h2>
<div class="lb-trans"><h2>OmniAb 股票表现</h2>
</div><p>The firm has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.78. The stock has a market cap of $273.52 million, a P/E ratio of -3.28 and a beta of 0.13.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 1.80 美元，200 日简单移动平均线为 1.78 美元。该股票的市值为 2.7352 亿美元，市盈率为-3.28，贝塔值为 0.13。</p>
</div><p>OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to analysts' expectations of $5.64 million. As a group, equities research analysts predict that OmniAb, Inc. will post -0.61 EPS for the current year.</p>
<div class="lb-trans"><p>OmniAb（NASDAQ:OABI - 获取免费报告）最近于 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.14 美元，超出市场共识预期的-0.15 美元，超出幅度为 0.01 美元。OmniAb 的股本回报率为-23.14%，净利润率为-301.83%。该公司在本季度的收入为 224 万美元，而分析师预期为 564 万美元。整体来看，股票研究分析师预测 OmniAb, Inc.在本年度将发布-0.61 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at OmniAb</h2>
<div class="lb-trans"><h2>OmniAb 内部买卖情况</h2>
</div><p>In other OmniAb news, CFO Kurt A. Gustafson sold 23,922 shares of the firm's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $1.96, for a total transaction of $46,887.12. Following the transaction, the chief financial officer owned 252,688 shares of the company's stock, valued at approximately $495,268.48. This trade represents a 8.65% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Matthew W. Foehr sold 13,666 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $1.96, for a total transaction of $26,785.36. Following the sale, the chief executive officer owned 4,360,083 shares in the company, valued at $8,545,762.68. This trade represents a 0.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 45,632 shares of company stock valued at $89,439. Company insiders own 8.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 OmniAb 新闻中，首席财务官 Kurt A. Gustafson 于 12 月 8 日星期一出售了 23,922 股该公司的股票。股票以平均价格 1.96 美元出售，总交易额为 46,887.12 美元。交易后，首席财务官持有该公司 252,688 股股票，价值约 495,268.48 美元。此交易代表其持股比例下降了 8.65%。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接获取。此外，首席执行官 Matthew W. Foehr 于 12 月 8 日星期一出售了 13,666 股该公司的股票。股票以平均价格 1.96 美元出售，总交易额为 26,785.36 美元。出售后，首席执行官持有该公司 4,360,083 股股票，价值 8,545,762.68 美元。此交易代表其持股比例下降了 0.31%。有关此销售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售公司股票 45,632 股，价值 89,439 美元。公司内部人士持有公司股票的 8.60%。</p>
</div><h2>Institutional Investors Weigh In On OmniAb</h2>
<div class="lb-trans"><h2>机构投资者对 OmniAb 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new position in OmniAb during the second quarter valued at about $168,000. Connors Investor Services Inc. raised its position in OmniAb by 25.0% in the second quarter. Connors Investor Services Inc. now owns 62,000 shares of the company's stock worth $108,000 after acquiring an additional 12,389 shares in the last quarter. Towerview LLC lifted its holdings in OmniAb by 43.3% in the 2nd quarter. Towerview LLC now owns 831,100 shares of the company's stock valued at $1,446,000 after acquiring an additional 251,100 shares during the last quarter. Private Management Group Inc. boosted its position in shares of OmniAb by 1.1% during the 2nd quarter. Private Management Group Inc. now owns 2,558,045 shares of the company's stock valued at $4,451,000 after purchasing an additional 28,286 shares in the last quarter. Finally, Isthmus Partners LLC boosted its position in shares of OmniAb by 21.2% during the 2nd quarter. Isthmus Partners LLC now owns 568,043 shares of the company's stock valued at $988,000 after purchasing an additional 99,336 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该公司的持股。俄亥俄州公共雇员退休系统在第二季度购买了 OmniAb 的新头寸，价值约 168,000 美元。Connors Investor Services Inc.在第二季度将其在 OmniAb 的持股增加了 25.0%。Connors Investor Services Inc.目前持有 62,000 股该公司的股票，价值 108,000 美元，此前在上个季度又购买了 12,389 股。Towerview LLC 在第二季度将其在 OmniAb 的持股增加了 43.3%。Towerview LLC 目前持有 831,100 股该公司的股票，价值 1,446,000 美元，此前在上个季度又购买了 251,100 股。Private Management Group Inc.在第二季度将其在 OmniAb 的持股增加了 1.1%。Private Management Group Inc.目前持有 2,558,045 股该公司的股票，价值 4,451,000 美元，此前在上个季度又购买了 28,286 股。最后，Isthmus Partners LLC 在第二季度将其在 OmniAb 的持股增加了 21.2%。Isthmus Partners LLC 目前持有 568,043 股该公司的股票，价值 988,000 美元，此前在上个季度又购买了 99,336 股。目前 72.08% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>OmniAb Company Profile</h2>
<div class="lb-trans"><h2>OmniAb 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.</p>
<div class="lb-trans"><p>OmniAb, Inc. NASDAQ: OABI 是一家生物技术公司，专注于治疗性抗体的发现和开发。该公司的综合抗体发现平台结合了专有的转基因动物模型、体外筛选和计算机工程，以加速候选药物的识别和优化。OmniAb 提供按服务收费的合作和许可协议，使生物制药合作伙伴能够利用其技术组合，涵盖肿瘤学、免疫学和其他治疗领域。</p>
</div><p>Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.</p>
<div class="lb-trans"><p>OmniAb 成立于 2016 年，总部位于华盛顿州西雅图，于 2021 年 5 月上市。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than OmniAb</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 OmniAb 更好</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OmniAb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 OmniAb 吗？</h2>
</div><p>Before you consider OmniAb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 OmniAb 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 OmniAb 并不在名单上。</p>
</div><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OmniAb 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

OmniAb（NASDAQ 代码：OABI）股价上涨 3.3% - 接下来会如何发展？